That is one of the important reasons that forced Microsoft to announce Windows 10X in 2019. This lighter and more compact version of Windows 10 will be perfectly suited for cheap tablets, laptops, and even devices. be mobile. Microsoft wants to focus more on Windows 10 instead of sharing resources with Windows 10X A supposedly near-final build of Windows 10X has even leaked, and Microsoft is reportedly ready to release the platform in the spring. After that, the timeline was moved to the end of next fall. It seems the software giant wants to stop this entire project in order to focus more on Windows 10. The cause of Microsoft’s change was based on the operating system not ready to meet the company’s expectations, the insider said. This is especially true as the pandemic period has seen increasing use of traditional Windows 10 PCs. This operating system also does not support traditional Win32 applications. Additionally, the report says corporate executives feel Windows 10X doesn’t provide the solutions their customers want.

The US pharmaceutical company Johnson & Johnson is postponing the launch of its vaccine in Europe. Reports of sinus vein thrombosis have been received and the decision has therefore been made to delay, the company said. The cases would now be investigated with experts and the authorities. The US health authority CDC and the FDA had previously recommended a temporary suspension of vaccinations with the Johnson & Johnson active ingredient. Six people in the US were diagnosed with sinus vein thrombosis between six and 13 days after vaccination, the authorities said in a joint statement. In three cases, thrombocytopenia, i.e. a lack of blood platelets, also occurred. They are women between the ages of 18 and 48 years.

Inoculated more than 6.8 million doses

According to the authorities, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States to date. The vaccine, of which only one dose is sufficient for vaccination protection, received US approval at the end of February. The now recommended suspension of vaccinations is a precautionary measure until exact results are available, said the CDC and FDA.

No decision for Germany

A spokesman for the federal health department said they had not yet decided how to proceed after the US warnings. “We always take such warnings seriously and follow them up.” The spokesman also referred to the responsibility of the Paul Ehrlich Institute. The vaccine from Johnson & Johnson was also approved in the EU in mid-March, but, unlike in the USA, is not yet in use here. The EU Commission assumes that the vaccine will be delivered to the EU next week. A total of 55 million cans are to be delivered in the second quarter, a good ten million of them to Germany. The Johnson & Johnson vaccine is the second corona vaccine that is suspected to be associated with the occurrence of sinus vein thrombosis. Previously, some countries had temporarily suspended vaccinations with the AstraZeneca vaccine, including Germany.